Opendata, web and dolomites

ADAPTED SIGNED

Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADAPTED project word cloud

Explore the words cloud of the ADAPTED project. It provides you a very rough idea of what is the project "ADAPTED" about.

experiments    broad    endocytosis    earliest    rising    diagnostics    harmonised    largely    biology    treatment    modulation    validation    pluripotent    co    25    embark    genotypes    organ    form    combined    metabolism    validating    progression    macrophage    dating    consistency    mci    biomarkers    lipid    diagnostic    free    proteomics    quantitative    combination    demands    chip    unknown    mechanisms    biological    cells    proof    performed    temporal    vision    follow    phenotype    human    lines    leverage    tide    neuron    brain    effort    dimension    back    predictive       culture    suffering    fundamental    signatures    hypothesis    identification    generate    utility    stem    longitudinal    proposes    rigorous    ipsc    bespoke    stages    astrocyte    risk       pleiotropic    attenuate    homeostasis    immune    apoe    extreme    models    cohorts    series    marker    uncover    cohort    capacity       influence    seminal    assays    backbone    omics    ad    endothelium    illuminate    vasculature    create    therapies    focussed    data    homozygote    load    blood    clinical    signalling    differentiate    editing    complexity    gene    acts   

Project "ADAPTED" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO ACE 

Organization address
address: MARQUES DE SENTMENAT 57
city: BARCELONA
postcode: 8014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://imi-adapted.eu
 Total cost 6˙796˙740 €
 EC max contribution 3˙510˙000 € (52%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-05-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO ACE ES (BARCELONA) coordinator 333˙757.00
2    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 688˙476.00
3    UNIVERSITEIT LEIDEN NL (LEIDEN) participant 470˙677.00
4    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 429˙850.00
5    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 420˙500.00
6    MIMETAS BV NL (Leiden) participant 305˙102.00
7    CAEBI BIOINFORMATICA SOCIEDAD LIMITADA ES (SEVILLA) participant 282˙062.00
8    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 244˙812.00
9    DC BIOSCEINCES LTD UK (DUNDEE) participant 186˙514.00
10    MODUS RESEARCH AND INNOVATION LIMITED UK (EDINBURGH) participant 110˙337.00
11    KITE INNOVATION (EUROPE) LIMITED UK (HUDDERSFIELD) participant 37˙912.00
12    ABBVIE DEUTSCHLAND GMBH & CO KG DE (WIESBADEN) participant 0.00
13    BIOGEN IDEC LIMITED UK (MAIDENHEAD) participant 0.00
14    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00

Map

 Project objective

APOEɛ4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect both the vasculature and the brain. This complexity and pleiotropic influence demands an integrated hypothesis-free approach to embark on a fundamental study of the gene, the phenotype and modulation by other risk factors. ADAPTED proposes to leverage extreme genotypes from consortium cohorts dating back more than 25 years to generate, and use existing, lines of human induced pluripotent stem cells (iPSC). These cells, with blood cells, will form the backbone of the research programme. We will differentiate them to the most relevant cells for APOE and AD studies and with gene editing create bespoke homozygote ɛ3 and ɛ2 cells for a highly focussed effort on APOE biology. A series of experiments including neuron-astrocyte and macrophage-endothelium co-culture and Organ on a Chip models combined with state-of-the-art omics including quantitative proteomics assays will generate data for rigorous integrated analysis to uncover new signalling pathways related to APOE. Lipid homeostasis, endocytosis, metabolism and immune systems pathways will be investigated in a broad approach. The findings are expected to lead to identification of new treatment approaches and blood based AD signatures with a temporal dimension from the earliest stages of risk identification and progression through MCI to AD. Testing and validation of biomarkers will be performed by examining their influence and predictive capacity in a longitudinal ADAPTED cohort harmonised using a combination of approaches for marker and diagnostic consistency. The impact of this work can be expected to include seminal new finding to illuminate the research path towards new diagnostics and therapies to attenuate the rising tide of suffering from AD. The vision is a follow on with clinical proof of concept validating utility of the results within two years of the end of ADAPTED.

 Deliverables

List of deliverables.
Definition of cognitive composite scores to evaluate rate of disease progression based on cognitive function decline in the ADAPTED cohorts Websites, patent fillings, videos etc. 2020-04-08 21:10:07

Take a look to the deliverables list in detail:  detailed list of ADAPTED deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Michael Peitz, Tamara Bechler, Catrin Cornelia Thiele, Monika Veltel, Melanie Bloschies, Klaus Fliessbach, Alfredo Ramirez, Oliver Brüstle
Blood-derived integration-free iPS cell line UKBi011-A from a diagnosed male Alzheimer\'s disease patient with APOE ɛ4/ɛ4 genotype
published pages: 250-253, ISSN: 1873-5061, DOI: 10.1016/j.scr.2018.04.011
Stem Cell Research 29 2020-04-08
2018 Sven J. van der Lee, Charlotte E. Teunissen, René Pool, Martin J. Shipley, Alexander Teumer, Vincent Chouraki, Debora Melo van Lent, Juho Tynkkynen, Krista Fischer, Jussi Hernesniemi, Toomas Haller, Archana Singh-Manoux, Aswin Verhoeven, Gonneke Willemsen, Francisca A. de Leeuw, Holger Wagner, Jenny van Dongen, Johannes Hertel, Kathrin Budde, Ko Willems van Dijk, Leonie Weinhold, M. Arfan Ikram, Maik Pietzner, Markus Perola, Michael Wagner, Nele Friedrich, P. Eline Slagboom, Philip Scheltens, Qiong Yang, Robert E. Gertzen, Sarah Egert, Shuo Li, Thomas Hankemeier, Catharina E.M. van Beijsterveldt, Ramachandran S. Vasan, Wolfgang Maier, Carel F.W. Peeters, Hans Jörgen Grabe, Alfredo Ramirez, Sudha Seshadri, Andres Metspalu, Mika Kivimäki, Veikko Salomaa, Ayşe Demirkan, Dorret I. Boomsma, Wiesje M. van der Flier, Najaf Amin, Cornelia M. van Duijn
Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies
published pages: , ISSN: 1552-5260, DOI: 10.1016/j.jalz.2017.11.012
Alzheimer\'s & Dementia 2020-04-08
2018 Nienke R. Wevers, Dhanesh G. Kasi, Taylor Gray, Karlijn J. Wilschut, Benjamin Smith, Remko van Vught, Fumitaka Shimizu, Yasuteru Sano, Takashi Kanda, Graham Marsh, Sebastiaan J. Trietsch, Paul Vulto, Henriëtte L. Lanz, Birgit Obermeier
A perfused human blood–brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport
published pages: , ISSN: 2045-8118, DOI: 10.1186/s12987-018-0108-3
Fluids and Barriers of the CNS 15/1 2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADAPTED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADAPTED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More